Real-world severe COVID-19 outcomes associated with use of antivirals and neutralising monoclonal antibodies in Scotland
DOI: 10.1038/s41533-024-00374-x.
Paper authors: Holly Tibble, Tanja Mueller, Euan Proud, Elliott Hall, Amanj Kurdi, Chris Robertson, Marion Bennie, Lana Woolford, Lynn Laidlaw, Kamil Sterniczuk and Aziz Sheikh
Journal: npj Primary Care Respiratory Medicine
This analysis is part of the Early Assessment of COVID-19 epidemiology and Vaccine/anti-viral Effectiveness (EAVE II) study. EAVE II is funded by the Medical Research Council (MR/R008345/1) with the support of BREATHE - The Health Data Research Hub for Respiratory Health [MC_PC_19004], which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. Additional support has been provided through the Scottish Government DG Health and Social Care.
This study was supported by the Medical Research Council [grant number UKRIMC_PC19075] and the National Institute for Health and Care Research [award number NIHR135575].